Cytokinetics Inc (NASDAQ: CYTK) is -35.43% lower on its value in year-to-date trading and has touched a low of $29.31 and a high of $61.38 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $36.62 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $36.59, the stock is 8.43% and 9.73% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing -0.10% at the moment leaves the stock -17.31% off its SMA200. CYTK registered -22.22% loss for a year compared to 6-month loss of -25.61%. The firm has a 50-day simple moving average (SMA 50) of $33.3466 and a 200-day simple moving average (SMA200) of $44.2514.
The stock witnessed a 10.44% gain in the last 1 month and extending the period to 3 months gives it a 5.84%, and is 6.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.16% over the week and 4.21% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $4.37B and $19.22M in sales. Profit margin for the company is -3201.47%. Distance from 52-week low is 24.84% and -40.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-125.03%).
The EPS is expected to shrink by -8.95% this year
484.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 120.45% of the company’s shares. The shares outstanding are 119.22M, and float is at 116.79M with Short Float at 11.99%. Institutions hold 119.58% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317 of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 10.5485 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 10.4702 and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
Cytokinetics Inc disclosed in a document filed with the SEC on Jul 08 ’25 that Malik Fady Ibraham (EVP Research & Development) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Jul 08 ’25 and was made at $33.76 per share for $67520.0. Following the transaction, the insider now directly holds 0.14 million shares of the CYTK stock.
Still, SEC filings show that on Jul 01 ’25, Blum Robert I (President & CEO) disposed off 5,000 shares at an average price of $33.55 for $0.17 million. The insider now directly holds 398,108 shares of Cytokinetics Inc (CYTK).
